Another study indicated that non-GCB DLBCL patients with CD79B mutations, higher TCL1A expression, or high MYC/BCL-2 expression have clinical benefits to zanubrutinib monotherapy or combination therapy (29). Here, BCL2 is linked to diffuse large B-cell lymphoma.